Drug intelligence / Profile preview

CR-2

Development stage: Preclinical
Lead developer: Curome Biosciences
Modality: Small Molecules

Overview

CR-2 is an early-stage investigational drug candidate being developed by CuromeBiosciences. It is currently positioned in the company's pipeline for the treatment of rare diseases. Detailed information regarding its specific molecular target, mechanism of action, and modality has not yet been publicly released, with the developer indicating that further details are forthcoming. The drug is part of a broader pipeline at CuromeBiosciences that includes NQO1 modulators, although it is not yet confirmed if CR-2 shares this specific mechanism.

Other names: CD21 modulatorsCD-21 modulatorsCD 21 modulators

Targets

CR2 (Complement receptor type 2)

Beyond the preview

Go deeper on CR-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-2.

Explore the full profile